Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108007
Title:
Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
Authors:
Thatcher, Nick; Wagstaff, John; Mene, A R; Smith, David B; Orton, C; Craig, P
Abstract:
Seventy-nine patients with Stage III widely metastatic melanoma were prospectively randomised to a 'no treatment' control group who received on tumour progression DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D 1.5 mg/m2 on Day 1. A total of six courses at 3-week intervals was given. Chemotherapy was only given on progression of disease. The other group received initially Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses and then the same chemotherapy on evidence of progressive disease. Minimum follow up time is 3 yr. The chemotherapy response rate (control 37%, C. parvum 24%) was not statistically different nor was the effect of chemotherapy on the site of individual metastases. Radiotherapy responses for irradiated soft tissue disease again were not significantly different, between the two patient groups. No significant differences in survival (control group median, 4 months, range 1-46; C. parvum median 3 months range 1-35) were observed and only one patient is alive at 35 months. The pattern of relapse was also similar in both groups. Reduction in haematological toxicity consequent on chemotherapy was not observed in the C. parvum-treated patients. No additional benefit was observed when C. parvum was followed by DTIC and Actinomycin D chemotherapy compared with the results from the chemotherapy given alone, although C. parvum on this schedule had minimal toxicity.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, U.K.
Citation:
Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. 1986, 22 (8):1009-14 Eur J Cancer Clin Oncol
Journal:
European Journal of Cancer & Clinical Oncology
Issue Date:
Aug-1986
URI:
http://hdl.handle.net/10541/108007
DOI:
10.1016/0277-5379(86)90069-6
PubMed ID:
3770045
Type:
Article
Language:
en
ISSN:
0277-5379
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorMene, A Ren
dc.contributor.authorSmith, David Ben
dc.contributor.authorOrton, Cen
dc.contributor.authorCraig, Pen
dc.date.accessioned2010-07-21T10:10:20Z-
dc.date.available2010-07-21T10:10:20Z-
dc.date.issued1986-08-
dc.identifier.citationCorynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma. 1986, 22 (8):1009-14 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379-
dc.identifier.pmid3770045-
dc.identifier.doi10.1016/0277-5379(86)90069-6-
dc.identifier.urihttp://hdl.handle.net/10541/108007-
dc.description.abstractSeventy-nine patients with Stage III widely metastatic melanoma were prospectively randomised to a 'no treatment' control group who received on tumour progression DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D 1.5 mg/m2 on Day 1. A total of six courses at 3-week intervals was given. Chemotherapy was only given on progression of disease. The other group received initially Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses and then the same chemotherapy on evidence of progressive disease. Minimum follow up time is 3 yr. The chemotherapy response rate (control 37%, C. parvum 24%) was not statistically different nor was the effect of chemotherapy on the site of individual metastases. Radiotherapy responses for irradiated soft tissue disease again were not significantly different, between the two patient groups. No significant differences in survival (control group median, 4 months, range 1-46; C. parvum median 3 months range 1-35) were observed and only one patient is alive at 35 months. The pattern of relapse was also similar in both groups. Reduction in haematological toxicity consequent on chemotherapy was not observed in the C. parvum-treated patients. No additional benefit was observed when C. parvum was followed by DTIC and Actinomycin D chemotherapy compared with the results from the chemotherapy given alone, although C. parvum on this schedule had minimal toxicity.en
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshDacarbazine-
dc.subject.meshDactinomycin-
dc.subject.meshHumans-
dc.subject.meshMelanoma-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPropionibacterium acnes-
dc.subject.meshProspective Studies-
dc.subject.meshRandom Allocation-
dc.titleCorynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, U.K.en
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.